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OBJECTIVES The study assessed the influence of lesion length and reference vessel diameter (RVD) on
recurrent restenosis after gamma intracoronary radiation therapy (ICRT) for in-stent
restenosis (IRS).
BACKGROUND Intracoronary radiation therapy reduces angiographic and clinical restenosis in patients with
ISR. The impact of ICRT on challenging subgroups, such as long lesions and small vessels,
has not been established.
METHODS Six-month quantitative coronary angiography and clinical follow-up were conducted to
evaluate the influence of lesion length and RVD in patients with ISR treated with ICRT who
were enrolled in gamma radiation trials. Angiographic binary restenosis (50% diameter
stenosis) and clinical events were assessed in 311 patients treated with gamma ICRT and 105
patients who received placebo.
RESULTS Baseline demographic, angiographic and procedural details were similar in the two treatment
groups. The ICRT group had reduced binary restenosis in vessels of all sizes (30% vs. 66%,
p  0.001), with the most benefit seen in small vessels. A trend toward reduced restenosis
with ICRT was found across all lesion lengths. At six months, major adverse cardiac events
(MACE) were reduced in the ICRT group compared to placebo (34% vs. 71%, p  0.0001),
driven by reduced target vessel revascularization (27% vs. 71%, p 0.0001). The independent
predictors of angiographic restenosis include ICRT (OR [odds ratio] 0.16; CI [confidence
interval] 0.10 to 0.28, p  0.001), lesion length (OR 1.03; CI 1.01 to 1.05, p  0.004) and
RVD (OR 0.40; CI 0.23 to 0.67, p  0.001).
CONCLUSIONS Intracoronary radiation therapy, compared to placebo, results in a significant reduction of
angiographic restenosis across all vessel sizes, with a trend toward reduction of angiographic
restenosis across all lesion lengths; this effect is seen predominantly in small vessels and diffuse
lesions. (J Am Coll Cardiol 2002;39:1290–6) © 2002 by the American College of
Cardiology Foundation
Postangioplasty restenosis is a major limitation of coronary
interventions, and it has been significantly reduced with the
widespread application of coronary stents (1,2). While
coronary stenting has progressively evolved with improve-
ment in stent design and deployment strategies, the treat-
ment of in-stent restenosis (ISR) remains a challenge.
Lesion length is recognized as a predictor of recurrent
restenosis, with the highest rates found in diffuse lesions
(10 mm) (3–5). The incidence of restenosis is higher after
stenting in smaller compared to larger vessels (6,7). Intra-
coronary radiation therapy (ICRT) reduces angiographic
and clinical restenosis in patients with ISR (8,9). The
impact of lesion length and reference vessel diameter (RVD)
on the rate of recurrent restenosis in patients treated with
ICRT has yet to be established. The purpose of this study
was to assess the influence of lesion length and RVD on
six-month angiographic and clinical outcomes in irradiated
and placebo-treated patients with ISR.
METHODS
Four hundred and sixteen consecutive patients enrolled in
the Washington Radiation for In-Stent restenosis Trial
(WRIST) series of gamma radiation studies (192Iridium),
conducted at the Washington Hospital Center between
February 1997 and June 2000, were selected for this study.
These trials were designed to test the effectiveness of
radiation as adjunctive treatment to conventional interven-
tion of ISR. The selected cohort included patients treated
with either radiation or placebo therapy who had completed
six-month angiographic follow-up. Patients were included
from the randomized, double-blinded WRIST and Long
WRIST (long ISR lesions 36 to 80 mm) trials, and from
gamma radiation registries including: Long WRIST High
Dose (long ISR lesions, 36 to 80 mm in length using 18 Gy
at 2 mm from the source); Plavix WRIST (six-month
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clopidogrel therapy postcoronary intervention and radia-
tion); Compassionate WRIST (intracoronary localized ra-
diation compassionate protocol for prevention of recurrence
of restenosis); and WRIST X-over (patients who initially
failed placebo therapy and were subsequently treated with
radiation).
All studies involved an Investigational Device Exemption
granted by the Food and Drug Administration, and they
were approved by the Institutional Review Board and the
Radiation Safety Committee at the Washington Hospital
Center. Informed consent was obtained for all patients.
The inclusion criteria included ISR, lesion diameter
stenosis50%, RVD 2.5 to 5.0 mm, lesion length80 mm
and successful primary coronary intervention. Exclusion
criteria included acute myocardial infarction (MI) 72 h,
left ventricular ejection fraction (LVEF) 20%, angio-
graphic visible thrombus, multiple coronary lesions and
prior radiation therapy.
Radiation delivery system and dosimetry. In the WRIST
series examined in this study, radiation was delivered via a
closed end-lumen 5F noncentered catheter (Medtronic
Vascular Interventional, Minneapolis, Minnesota), with
patients receiving a nylon ribbon (0.003-in. diameter) con-
taining different seed trains of either 192Iridium or placebo,
positioned with at least a 4-mm overlap of the normal
segments on each end. The radiation oncologist hand-
loaded the ribbon from a lead container into the closed
end-lumen catheter. Depending on the study protocol, the
prescribed dose was 15 to 18 Gy at 2.0 mm from the surface
of the source for vessels between 2.5 and 4.0 mm, and 15 to
18 Gy at 2.4 mm for vessels 4.0 mm in diameter. The
mean specific activity of the seeds was 25.9 4.1 mCi, with
varying seed trains required to cover different lesion lengths.
Coronary intervention details. Interventional procedures
included balloon angioplasty, excimer laser coronary angio-
plasty, rotational atherectomy and/or additional stent im-
plantation. Device selection for the coronary intervention
was based on lesion morphology and was at the discretion of
the operator. A final angiogram was performed following
radiation to ensure 30% final diameter stenosis. All
patients received routine postangioplasty care and were
discharged on aspirin (325 mg daily) and additional anti-
platelet therapy, including ticlopidine 500 mg oral bolus and
250 mg twice daily continued for one month, or clopidogrel
300 mg oral bolus followed by 75 mg daily continued for
either 30 days or six months (depending on the study
protocol).
Patient follow-up. Data were prospectively recorded and
forwarded to the Data Coordinating Center (Cardiology
Research Institute Data Analysis Center at the Washington
Hospital Center, Washington, D.C.). Clinical, angio-
graphic and procedural details were recorded at baseline,
in-hospital and at six-month follow-up (taken as within 220
days of the index procedure to ensure the entire cohort was
included in the analysis). An adjudication committee inde-
pendently reviewed all clinical events.
Quantitative coronary angiography (QCA). All patients
received six-month follow-up coronary angiography, with
QCA performed at the Washington Hospital Center labo-
ratory using the CMS–GFT system (Medis, The Nether-
lands). Angiographic measurements were performed on the
entire artery segment covered by the radiation therapy. Late
loss (mm) was defined as the change in lesion minimal
luminal diameter (MLD) from the final to the follow-up
angiogram. The arithmetic late loss index was defined as
late loss/acute gain (increase in MLD from pre- to post-
intervention angiogram). Angiographic binary restenosis at
six-month follow-up was defined as 50% diameter nar-
rowing. This was determined both for the stented segment
and the segment including the stent and its edges (within
5 mm of stent).
Definitions. Death was defined as all-cause mortality.
Myocardial infarction was defined as a total creatinine
kinase elevation3 times the baseline value and/or elevated
creatinine kinase-MB fraction 20 ng/ml, with or without
new pathological Q waves (0.4 ms), in two or more
contiguous leads. Target lesion revascularization (TLR)
refers to the need for repeat percutaneous intervention or
cardiac surgery due to restenosis at the site of the treated
lesion. Target vessel revascularization (TVR) is defined as
the need for repeat percutaneous intervention or cardiac
surgery due to restenosis at the site of the treated lesion or
a diseased segment in the target vessel distinct from the
target lesion. Both TLR and TVR were driven by clinical
signs of ischemia in the presence of angiographic restenosis.
Major adverse cardiac events (MACE) were defined as
death, Q-wave MI and/or TLR/TVR. Late total occlusion
(LTO) was defined as angiographically documented total
occlusion at the lesion site 30 days and within six months
of the index procedure.
Abbreviations and Acronyms
CI  confidence interval
ICRT  intracoronary radiation therapy
ISR  in-stent restenosis
IVUS  intravascular ultrasound
LTO  late total occlusion
LVEF  left ventricular ejection fraction
MACE  major adverse cardiac events
MI  myocardial infarction
MLD  minimal luminal diameter
OR  odds ratio
PTCA  percutaneous transluminal coronary
angioplasty
QCA  quantitative coronary angiography
RVD  reference vessel diameter
SCRIPPS  Scripps Coronary Radiation to Inhibit
Proliferation Post Stenting
TLR  target lesion revascularization
TVR  target vessel revascularization
WRIST  Washington Radiation for In-Stent
restenosis Trial
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Statistical analysis. Continuous variables were expressed
as means  SD, and categorical data were expressed as
percentages. To analyze the efficacy of ICRT, the Student t
test was used to compare continuous variables; chi-square
test or the Fisher exact test was used to assess discrete
variables. Stepwise logistic regression was used to determine
independent predictors of angiographic binary restenosis
and MACE (TVR). The variables used in this analysis
included ICRT, age, gender, hypertension, diabetes, history
of smoking, hypercholesterolemia, history of MI, history of
coronary artery bypass grafting, history of percutaneous
transluminal coronary angioplasty (PTCA), unstable an-
gina, multivessel disease, LVEF, location of treated vessel,
lesion length, RVD and the pre- and postintervention
MLD. Independent variables are expressed as an odds ratio
(OR) with 95% confidence intervals (CI). A value of p 
0.05 was considered statistically significant. The association
of angiographic restenosis with lesion length and RVD was
expressed by probability curves based on logistic regression.
RESULTS
Of the 416 patients enrolled in this cohort from the
WRIST series, 311 were treated with active radiation and
105 with placebo. The baseline clinical, lesion and proce-
dural characteristics were similar between the two groups
(Table 1). Overall, 38% of patients were diabetic, 50% had
multivessel disease and 53% had previous treatment of ISR,
representing a high-risk cohort. Atheroablative devices were
predominantly used for ISR, with 56% of patients treated
with rotational atherectomy. Additional stenting was em-
ployed in 44% of patients. Radiation was delivered and
tolerated in all ICRT patients (mean dose 14.6  0.9 Gy,
dwell time 21.9  6.5 min).
QCA. The ISR lesions in both treated groups were pre-
dominantly diffuse (ICRT 22.9  11.8 mm vs. placebo
25.0  12.6 mm, p  NS), as outlined by QCA analysis
(Table 2). There were no coronary perforations or aneu-
rysms. In patients treated with adjunctive ICRT, follow-up
MLD (1.55  0.79 mm vs. 1.09  0.68 mm, p  0.001)
and diameter stenosis (48  26% vs. 61  21%, p  0.001)
were favorable as compared to placebo. Patients receiving
ICRT had reduced late loss (0.37  0.78 mm vs. 0.84 
0.62 mm, p  0.001), with an associated improved late loss
index (0.48  0.67 vs. 0.70  0.65, p  0.001), compared
to placebo, demonstrating a powerful ability to reduce
neointimal proliferation after coronary intervention. This
translated into reduced angiographic binary restenosis with
ICRT, both within the stent (24% vs. 61%, p  0.001) and
in the coronary segment involving the stent and its edges
(30% vs. 66%, p  0.001).
The ICRT showed a trend toward a reduction in six-
month angiographic restenosis across all lesion lengths (p
0.09) compared to placebo, especially in diffuse lesions (Fig.
1). In a similar analysis, ICRT resulted in reduced angio-
graphic restenosis across vessels of all sizes (p  0.03), with
the effect seen predominantly in small vessels (2.5 mm)
(Fig. 2). Angiographic restenosis was also assessed in
relation to both lesion length and RVD, demonstrating a
higher rate in long lesions and small vessels (Fig. 3). It is
this patient population that potentially derives the maximal
benefit from ICRT. Analysis of Figure 3 suggests that RVD
is a more influential factor (than lesion length) for angio-
graphic restenosis, which is supported by the statistical
difference of the probability curves (Figs. 1 and 2).
Clinical outcomes. Clinical events at six months among
the entire cohort are outlined (Table 3). Event-free survival
(freedom from death, MI and repeat revascularization) was
greater for patients assigned to ICRT compared to placebo
(68% vs. 29%, p  0.001). This difference was driven by
reduced rates of TLR (22% vs. 69%, p  0.001) and TVR
(27% vs. 71%, p 0.001). There were no differences in rates
of death or MI between each group. Late total occlusion was
a phenomenon related to ICRT (5% vs. 0%, p  0.015).
The independent predictors of angiographic restenosis and
MACE (TVR) at six months are outlined (Table 4).
Table 1. Baseline Characteristics of Radiation and Placebo-
Treated Patients
Characteristic
Radiation
(n  311)
Placebo
(n  105)
p
Value
Age (yrs) 61  10 61  10 NS
Male gender (%) 66 69 NS
Hypercholesterolemia (%) 92 94 NS
Diabetes (%) 37 42 NS
Hypertension (%) 74 76 NS
Smoking history (%) 61 68 NS
Previous myocardial infarction (%) 48 49 NS
Previous CABG (%) 45 49 NS
Previous in-stent restenosis (%) 55 45 NS
Unstable angina (%) 80 84 NS
CCS angina score III or IV (%) 75 72 NS
Multivessel disease (%) 48 54 NS
Left ventricular ejection fraction (%) 0.49  0.11 0.49  0.11 NS
CABG  coronary artery bypass grafting; CCS  Canadian Cardiovascular Society.
Table 2. Quantitative Coronary Angiography
Radiation
(n  311)
Placebo
(n  105)
p
Value
Lesion length (mm) 22.9  11.8 25.0  12.6 NS
RVD (mm) 2.91  0.45 2.66  0.54 NS
MLD (mm)
Pre- 0.87  0.46 0.76  0.42 0.02
Post- 1.89  0.44 1.91  0.42 NS
Follow-up 1.55  0.79 1.09  0.68  0.001
Diameter stenosis (%)
Pre- 67  16 71  15 0.02
Post- 31  12 30  12 NS
Follow-up 48  26 61  21  0.001
Late loss (mm) 0.37  0.78 0.84  0.62  0.001
Late loss index 0.48  0.67 0.70  0.65  0.001
Angiographic binary restenosis
(50%)
Stent 24 61  0.001
Stent and edges 30 66  0.001
MLD  minimal luminal diameter, RVD  reference vessel diameter.
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Radiation therapy, shorter lesion lengths and increased
RVD (larger vessels) significantly reduce these end points.
DISCUSSION
The principal findings of this study are as follows: 1) ICRT
using 192Iridium can be effectively and safely delivered to a
high-risk population of patients with ISR; 2) ICRT, com-
pared to placebo, shows a trend toward reduced angio-
graphic restenosis across all lesion lengths, especially with
diffuse lesions; 3) ICRT reduces angiographic restenosis in
all vessel sizes, with the effect seen predominantly in small
vessels (2.5 mm); 4) a higher rate of angiographic reste-
nosis was evident with a combination of long lesions and
small vessels, and it is this patient population that appears to
derive the maximal benefit from ICRT; 5) vessel size
(RVD) is a more influential predictor of angiographic
restenosis than lesion length; and 6) ICRT reduces late loss,
Figure 1. Angiographic restenosis related to lesion length.
Figure 2. Angiographic restenosis related to reference vessel diameter.
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Figure 3. Angiographic restenosis related to lesion length and reference vessel diameter. The p value was 0.05 comparing angiographic restenosis rates
of reference vessel diameter/lesion length subgroups between radiation-treated (A) and placebo-treated (B) patients, except in the group of lesions15 mm
in length in vessels 3.0 mm in diameter.
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angiographic binary restenosis within the stent (including
stent edges), and clinical MACE driven by reduced TVR.
Mechanism of restenosis. Restenosis is a problem of
exaggerated healing in the coronary artery after balloon
injury, with smooth muscle migration and proliferation
causing luminal compromise, in association with a lack of
compensatory vessel wall dilation (10). Following PTCA,
geometric remodeling is a critical response, with up to 73%
of late loss due to chronic vessel constriction (11). Stents
provide a scaffold for the vessel wall, and they largely
eliminate this pathologic remodeling (12). Serial intravas-
cular ultrasound (IVUS) studies in stented lesions show that
most late loss is due to neointimal proliferation distributed
over the length of the stent (13). Longer lesions with greater
plaque burden provide an increased source of smooth
muscle cells that will proliferate to form neointima (3,14).
Stenting elicits a relatively higher proliferative response in
small vessels. One explanation is that lumen gain in a small
vessel requires a relatively higher degree of vessel wall
stretch and thus creates more injury (7).
Efficacy of radiation. Use of ICRT has been shown to
reduce lesion formation following arterial injury in a variety
of animal models (15,16). Targeting the adventitia with an
effective dose of radiation to inhibit the proliferation of
adventitial myofibroblasts is one proposed key mechanism
of reducing restenosis (17). Adjunctive ICRT after PTCA
is efficacious, with the Scripps Coronary Radiation to
Inhibit Proliferation Post Stenting (SCRIPPS) study (9)
showing a 48% reduction in angiographic restenosis and a
58% reduction in composite MACE at three-year follow-
up. Consistent with the clinical efficacy, IVUS analysis from
the Gamma-1 study has shown that intimal hyperplasia is
reduced with 192Iridium compared to placebo controls (0.8 
1.0 mm2 vs. 1.6  1.2 mm2, p  0.007), when averaged
over the length of the stent. In the original WRIST and
SCRIPPS studies, ICRT with 192Iridium was the only
predictor of freedom from angiographic or clinical restenosis
(8,18). Our study is the first to show that both lesion length
and RVD (in addition to ICRT) are important predictors in
assessing risk of recurrent ISR.
Long lesions and small vessels. The mean lesion length in
our cohort predominately represents diffuse ISR, which has
been shown to be an independent predictor of TLR (OR
1.7, p  0.038) following conventional therapy for ISR,
predating ICRT (19). The IVUS analysis of radiated ISR
lesions (mean length 56  14 mm) from Long WRIST,
when compared to WRIST, revealed an increased intimal
hyperplasia cross-sectional area and a greater variability in
neointimal response along the length of the stent (20). This
supports the notion that long lesions are more challenging
and may require higher dose prescriptions to eliminate the
increasing probability of restenosis (Fig. 1). Long WRIST
high dose was associated with a similar increase in mean
intimal hyperplasia cross-sectional area (0.6  1.5 mm2 vs.
0.6  1.1 mm2) compared to the Long WRIST group,
despite longer lesions (mean 66  17 mm) in the high-dose
patients. Long ISR lesions also predict LTO and late
thrombosis (OR 1.15, p  0.04) especially in conjunction
with radiation and additional stenting (21).
Endeavors to achieve the largest final MLD appear
justified as larger vessels have less restenosis (known as the
“bigger is better” hypothesis). The risk of a bigger lumen is
more injury and exaggerated intimal hyperplasia (22). The
limitation of ISR analysis in small vessels (RVD 2.5 mm)
is that this subset has largely been excluded from radiation
trials to date. In the current study, smaller vessels derive the
maximum benefit from ICRT. The concept of freezing the
final angiographic result with radiation and, in some in-
stances, melting the residual stenosis (as seen in an IVUS
subset of WRIST patients), is a potential explanation for
our findings that smaller vessels have the greatest relative
benefit.
Study limitations. These gamma radiation studies were
not specifically designed to test the impact of lesion length
and RVD on angiographic and clinical outcomes. Although
this is a retrospective single-center experience, it is based on
data acquired prospectively from the WRIST series that
have similar entry criteria and clinical characteristics. Pa-
tients were subjected to an independent adjudication com-
mittee providing reliability to the observations.
Table 3. Major Clinical Events at Six Months
No. (%)
Radiation
(n  311)
Placebo
(n  105)
p
Value
Death 7 (2) 4 (4) NS
Q-wave MI 3 (1) 0 (0) NS
Non–Q-wave MI 37 (12) 12 (11) NS
TLR 69 (22) 72 (69)  0.001
TVR 85 (27) 74 (71)  0.001
Non-TVR 24 (8) 11 (11) NS
CABG 31 (10) 11 (11) NS
Late total occlusion 15 (5) 0 (0) 0.015
MACE (TLR) 66 (21) 60 (57)  0.001
MACE (TVR) 105 (34) 75 (71)  0.001
CABG  coronary artery bypass grafting; MACE  major adverse cardiac events;
MI  myocardial infarction; TLR  target lesion revascularization; TVR  target
vessel revascularization.
Table 4. Predictors of Angiographic Restenosis and MACE
(TVR) at Six Months
No. (%) Odds Ratio CI p Value
Angiographic restenosis
Radiation 0.16 0.10–0.28  0.001
Reference vessel diameter 0.40 0.23–0.67  0.001
Lesion length 1.03 1.01–1.05 0.004
MACE (TVR)
Radiation 0.20 0.12–0.34  0.001
Reference vessel diameter 0.60 0.38–0.94 0.024
Lesion length 1.02 1.00–1.04 0.041
CI  confidence interval; MACE  major adverse cardiac events; TVR  target
vessel revascularization.
1295JACC Vol. 39, No. 8, 2002 Ajani et al.
April 17, 2002:1290–6 Angiographic Parameters Affecting Radiation Outcomes for ISR
CONCLUSIONS
Intracoronary radiation remains the foremost therapeutic
strategy in treating patients with ISR. This therapy using
192Iridium improves six-month outcomes compared to pla-
cebo and results in a reduced rate of angiographic restenosis
in all vessel sizes, predominantly small vessels (2.5 mm),
with a trend toward reduced restenosis across all lesion
lengths, especially long lesions (10 mm). The incidence of
angiographic restenosis is reduced most notably in small
vessels involving long lesions, and it is this patient popula-
tion that potentially derives the maximal benefit from
ICRT.
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